SEC Comment Letter 0000000000-23-001784 to Zeo ScientifiX, Inc. (ZEOX)

Zeo ScientifiX, Inc.
Date: Feb. 22, 2023 · CIK: 0001557376 · Accession: 0000000000-23-001784

View on Edgar

AI Filing Summary & Sentiment

Date

February 22, 2023

Author

Not clearly detected

Form

UPLOAD

Company

Zeo ScientifiX, Inc.

Letter

United States securities and exchange commission logo February 22, 2023 Ian Bothwell CFO Skycrest Holdings, LLC 1930 Harrison Street, Suite 204 Hollywood, FL 33020 Re:Organicell Regenerative Medicine, Inc. Schedule 13D/A filed by Skycrest Holdings, LLC Filed February 14, 2023 File No. 005-87575 Dear Ian Bothwell: We have reviewed the above-captioned filing and February 14, 2023 response to our comment letter and have the following comment. Unless we note otherwise, our references to prior comments are to comments in our January 20, 2023 letter. Schedule 13D/A filed February 14, 2023 General 1.We note your response to comment 2. The amended filing does not provide the required qualitative disclosure narrative for each item requirement of Schedule 13D, including any negative responses. See Rule 13d-1(a) and Instruction A. to Schedule 13D. While the staff of the Office of Mergers and Acquisitions will not undertake any further examination of the filer's non-compliance with this rule at this time, we reserve the right to make further inquiry into this matter and make any recommendations we deem appropriate. Please direct any questions to Michael Killoy (202) 551-7576 or Nicholas Panos at (202) 551-3266. Sincerely, Division of Corporation Finance Office of Mergers & Acquisitions cc: Edward Anderson

Show Raw Text

United States securities and exchange commission logo
February 22, 2023
Ian Bothwell
CFO
Skycrest Holdings, LLC
1930 Harrison Street, Suite 204
Hollywood, FL 33020
Re:Organicell Regenerative Medicine, Inc.
Schedule 13D/A filed by Skycrest Holdings, LLC
Filed February 14, 2023
File No. 005-87575
Dear Ian Bothwell:
            We have reviewed the above-captioned filing and February 14, 2023 response to our
comment letter and have the following comment.  Unless we note otherwise, our references to
prior comments are to comments in our January 20, 2023 letter.
Schedule 13D/A filed February 14, 2023
General
1.We note your response to comment 2.  The amended filing does not provide the required
qualitative disclosure narrative for each item requirement of Schedule 13D, including any
negative responses.  See Rule 13d-1(a) and Instruction A. to Schedule 13D.  While the
staff of the Office of Mergers and Acquisitions will not undertake any further examination
of the filer's non-compliance with this rule at this time, we reserve the right to make
further inquiry into this matter and make any recommendations we deem appropriate.
            Please direct any questions to Michael Killoy (202) 551-7576 or Nicholas Panos at (202)
551-3266.
Sincerely,
Division of Corporation Finance
Office of Mergers & Acquisitions
cc:       Edward Anderson

SecProbe.io